{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.115","value":"83966.099"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Pharmacokinetics of Durvalumab derived from serum concentration versus time data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Durvalumab 1500 mg + Daratumumab 16 mg/kg were administered intravenously within a 28-day cycle for a maximum of 60 cycles.","id":"OG000","title":"Simon Stage 1: D2 Arm"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least 1 dose of study medication and who have at least 1 measurable plasma concentration. \\[AUC(TAU)\\] was a pre-specified secondary outcome measure in the Simon Stage 1: D2 arm only.","reportingStatus":"POSTED","timeFrame":"Cycle 1 - Days 2, 8, 15, 22","title":"Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm","type":"SECONDARY","unitOfMeasure":"Hour*ug/mL"}